PDCD1 and urinary bladder carcinoma: TMB is another promising predictor for anti-PD-1/PD-L1 immunotherapy compared to dMMR/MSI-H, and the relevant content has been widely studied in lung cancer [88–92], melanoma [93], bladder cancer [94], and others.